-
Mashup Score: 3Segmenting the Utility of ADCs in NSCLC: How These Agents Are Affecting Second-Line Standards - 28 day(s) ago
Keeping investigators on the edge of their seats, new data from clinical trials evaluating ADCs continue to impress.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8I Am RETpositive: Who We Are - 30 day(s) ago
“There’s a lot of joy in the life you are given after a cancer diagnosis. It just may look a little different than the life you were expecting.” RETpositive …
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Segmenting the Utility of ADCs in NSCLC: How These Agents Are Affecting Second-Line Standards - 30 day(s) ago
Keeping investigators on the edge of their seats, new data from clinical trials evaluating ADCs continue to impress.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence - 1 month(s) ago
The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 27The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast - 1 month(s) ago
Oncology and Therapy – The identification of actionable biomarkers and development of targeted therapies have revolutionized the field of lung cancer treatment. In patients with advanced non-small…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence - 1 month(s) ago
The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Rezatapopt Yields Early Responses, Safety in Advanced Ovarian Cancer - 1 month(s) ago
Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 56
Correlations of overall response rate and progression-free survival with overall survival were generally moderate in this pooled analysis. The findings support routine analysis of mature overall survival data, where feasible, in first-line randomised trials of ICIs for metastatic NSCLC.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
Segmenting the Utility of ADCs in NSCLC: How These Agents Are Affecting Second-Line Standards @benlevylungdoc @hopkinskimmel #lcsm https://t.co/gxSQIiCSdP